TD Cowen analyst Tara Bancroft has maintained their bullish stance on OCUL stock, giving a Buy rating yesterday.
Tara Bancroft’s rating is based on several strategic decisions and developments by Ocular Therapeutix that enhance the potential of their clinical trials. The amendment to the SOL-1 trial to include redosing at weeks 52 and 76, while maintaining the primary endpoint at week 36, demonstrates a forward-thinking approach that could lead to a more flexible FDA label allowing for extended dosing intervals. This adjustment, approved by the FDA, is expected to provide valuable insights into the efficacy of Axpaxli, with topline data anticipated in the first quarter of 2026.
Furthermore, the reduction in the size of the SOL-R trial by one-third, without compromising the statistical power or dosing flexibility, suggests improved efficiency in their trial processes. This streamlining is expected to accelerate the timeline for obtaining topline data, potentially enhancing the company’s ability to meet FDA requirements more effectively. These strategic moves, combined with the progress in patient enrollment, underpin Bancroft’s confidence in the company’s future prospects, justifying the Buy rating for Ocular Therapeutix’s stock.
Bancroft covers the Healthcare sector, focusing on stocks such as Geron, Protagonist Therapeutics, and TG Therapeutics. According to TipRanks, Bancroft has an average return of -8.2% and a 26.21% success rate on recommended stocks.
In another report released yesterday, Needham also initiated coverage with a Buy rating on the stock with a $15.00 price target.